Loading…

Accelerated atherogenesis in autoimmune rheumatic diseases

The observation that systemic inflammatory rheumatic diseases such as rheumatoid arthritis (RA) are associated with a significantly increased rate of cardiovascular disease, which often occurs at a younger age than in the normal population, is particularly important given the increasing interest in...

Full description

Saved in:
Bibliographic Details
Published in:Autoimmunity reviews 2002-12, Vol.1 (6), p.338-347
Main Authors: Bacon, P.A, Stevens, R.J, Carruthers, D.M, Young, S.P, Kitas, G.D
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c394t-8780853fc4de29178b7b696c26a238907ffe03505326421a612f1cca376399ab3
cites cdi_FETCH-LOGICAL-c394t-8780853fc4de29178b7b696c26a238907ffe03505326421a612f1cca376399ab3
container_end_page 347
container_issue 6
container_start_page 338
container_title Autoimmunity reviews
container_volume 1
creator Bacon, P.A
Stevens, R.J
Carruthers, D.M
Young, S.P
Kitas, G.D
description The observation that systemic inflammatory rheumatic diseases such as rheumatoid arthritis (RA) are associated with a significantly increased rate of cardiovascular disease, which often occurs at a younger age than in the normal population, is particularly important given the increasing interest in the role of inflammation in atherogenesis in the general population. This review examines the accumulating evidence for accelerated atherogenesis of RA and updates the hypothesis that vasculitis plays a major role in this. Endothelial dysfunction (ECD), widely regarded as initial lesion in atherogenesis, has been shown to occur commonly in primary vasculitis. This ECD is a diffuse event, demonstrable in more than one vascular bed. It is not simply due to scarring in the vessel wall, related to the focal inflammation of the underlying vasculitis, since it may be reversed by suppression of the immune inflammation. However, the mechanisms for this ECD differ from that of the primary vasculitis. Preliminary evidence suggests that inflammatory mediators such as CRP, TNF, or sphingolipids may be involved. The diffuse ECD of vasculitis may have important consequences for both the progression of the primary disease and for cardiovascular events. A model for the role of vasculitis-induced ECD in the accelerated atherogenesis of rheumatic diseases is presented. These concepts are discussed together with the messages they suggest for ‘idiopathic’ atherosclerosis in the general population.
doi_str_mv 10.1016/S1568-9972(02)00100-3
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72905910</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1568997202001003</els_id><sourcerecordid>72905910</sourcerecordid><originalsourceid>FETCH-LOGICAL-c394t-8780853fc4de29178b7b696c26a238907ffe03505326421a612f1cca376399ab3</originalsourceid><addsrcrecordid>eNqFkN9LwzAQgIMobk7_BKVPog_VS9KmiS8yhr9g4IP6HNL06iJrO5NU8L-3c0N9Ew5yHN_l7j5CjilcUKDi8onmQqZKFewM2DkABUj5Dhn_lHf_5CNyEMLbAAnF1D4ZUSYzqaQak6uptbhEbyJWiYkL9N0rthhcSFybmD52rmn6FhO_wL4x0dmkcgFNwHBI9mqzDHi0fSfk5fbmeXafzh_vHmbTeWq5ymIqCwky57XNKmSKFrIsSqGEZcIwLhUUdY3Ac8g5ExmjRlBWU2sNLwRXypR8Qk43_658995jiLpxYVh6aVrs-qALpiBXFAYw34DWdyF4rPXKu8b4T01Br6Xpb2l6bUTDEGtpmg99J9sBfdlg9du1tTQA1xsAhzM_HHodrMPWYuU82qirzv0z4gusuXsB</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72905910</pqid></control><display><type>article</type><title>Accelerated atherogenesis in autoimmune rheumatic diseases</title><source>Elsevier:Jisc Collections:Elsevier Read and Publish Agreement 2022-2024:Freedom Collection (Reading list)</source><creator>Bacon, P.A ; Stevens, R.J ; Carruthers, D.M ; Young, S.P ; Kitas, G.D</creator><creatorcontrib>Bacon, P.A ; Stevens, R.J ; Carruthers, D.M ; Young, S.P ; Kitas, G.D</creatorcontrib><description>The observation that systemic inflammatory rheumatic diseases such as rheumatoid arthritis (RA) are associated with a significantly increased rate of cardiovascular disease, which often occurs at a younger age than in the normal population, is particularly important given the increasing interest in the role of inflammation in atherogenesis in the general population. This review examines the accumulating evidence for accelerated atherogenesis of RA and updates the hypothesis that vasculitis plays a major role in this. Endothelial dysfunction (ECD), widely regarded as initial lesion in atherogenesis, has been shown to occur commonly in primary vasculitis. This ECD is a diffuse event, demonstrable in more than one vascular bed. It is not simply due to scarring in the vessel wall, related to the focal inflammation of the underlying vasculitis, since it may be reversed by suppression of the immune inflammation. However, the mechanisms for this ECD differ from that of the primary vasculitis. Preliminary evidence suggests that inflammatory mediators such as CRP, TNF, or sphingolipids may be involved. The diffuse ECD of vasculitis may have important consequences for both the progression of the primary disease and for cardiovascular events. A model for the role of vasculitis-induced ECD in the accelerated atherogenesis of rheumatic diseases is presented. These concepts are discussed together with the messages they suggest for ‘idiopathic’ atherosclerosis in the general population.</description><identifier>ISSN: 1568-9972</identifier><identifier>EISSN: 1568-9972</identifier><identifier>DOI: 10.1016/S1568-9972(02)00100-3</identifier><identifier>PMID: 12848989</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Arteriosclerosis - etiology ; Arthritis, Rheumatoid - complications ; Atherosclerosis ; Autoimmune Diseases - complications ; C-Reactive Protein - physiology ; Cardiovascular disease ; Endothelium, Vascular - physiopathology ; Heart Diseases - etiology ; Humans ; Immunosuppression ; Inflammation ; Inflammation - etiology ; Lupus Erythematosus, Systemic - complications ; Models, Cardiovascular ; Rheumatic Diseases - complications ; Rheumatoid arthritis ; Sphingolipids - physiology ; Tumor Necrosis Factor-alpha - physiology ; Vasculitis ; Vasculitis - etiology</subject><ispartof>Autoimmunity reviews, 2002-12, Vol.1 (6), p.338-347</ispartof><rights>2002 Elsevier Science B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c394t-8780853fc4de29178b7b696c26a238907ffe03505326421a612f1cca376399ab3</citedby><cites>FETCH-LOGICAL-c394t-8780853fc4de29178b7b696c26a238907ffe03505326421a612f1cca376399ab3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12848989$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bacon, P.A</creatorcontrib><creatorcontrib>Stevens, R.J</creatorcontrib><creatorcontrib>Carruthers, D.M</creatorcontrib><creatorcontrib>Young, S.P</creatorcontrib><creatorcontrib>Kitas, G.D</creatorcontrib><title>Accelerated atherogenesis in autoimmune rheumatic diseases</title><title>Autoimmunity reviews</title><addtitle>Autoimmun Rev</addtitle><description>The observation that systemic inflammatory rheumatic diseases such as rheumatoid arthritis (RA) are associated with a significantly increased rate of cardiovascular disease, which often occurs at a younger age than in the normal population, is particularly important given the increasing interest in the role of inflammation in atherogenesis in the general population. This review examines the accumulating evidence for accelerated atherogenesis of RA and updates the hypothesis that vasculitis plays a major role in this. Endothelial dysfunction (ECD), widely regarded as initial lesion in atherogenesis, has been shown to occur commonly in primary vasculitis. This ECD is a diffuse event, demonstrable in more than one vascular bed. It is not simply due to scarring in the vessel wall, related to the focal inflammation of the underlying vasculitis, since it may be reversed by suppression of the immune inflammation. However, the mechanisms for this ECD differ from that of the primary vasculitis. Preliminary evidence suggests that inflammatory mediators such as CRP, TNF, or sphingolipids may be involved. The diffuse ECD of vasculitis may have important consequences for both the progression of the primary disease and for cardiovascular events. A model for the role of vasculitis-induced ECD in the accelerated atherogenesis of rheumatic diseases is presented. These concepts are discussed together with the messages they suggest for ‘idiopathic’ atherosclerosis in the general population.</description><subject>Arteriosclerosis - etiology</subject><subject>Arthritis, Rheumatoid - complications</subject><subject>Atherosclerosis</subject><subject>Autoimmune Diseases - complications</subject><subject>C-Reactive Protein - physiology</subject><subject>Cardiovascular disease</subject><subject>Endothelium, Vascular - physiopathology</subject><subject>Heart Diseases - etiology</subject><subject>Humans</subject><subject>Immunosuppression</subject><subject>Inflammation</subject><subject>Inflammation - etiology</subject><subject>Lupus Erythematosus, Systemic - complications</subject><subject>Models, Cardiovascular</subject><subject>Rheumatic Diseases - complications</subject><subject>Rheumatoid arthritis</subject><subject>Sphingolipids - physiology</subject><subject>Tumor Necrosis Factor-alpha - physiology</subject><subject>Vasculitis</subject><subject>Vasculitis - etiology</subject><issn>1568-9972</issn><issn>1568-9972</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><recordid>eNqFkN9LwzAQgIMobk7_BKVPog_VS9KmiS8yhr9g4IP6HNL06iJrO5NU8L-3c0N9Ew5yHN_l7j5CjilcUKDi8onmQqZKFewM2DkABUj5Dhn_lHf_5CNyEMLbAAnF1D4ZUSYzqaQak6uptbhEbyJWiYkL9N0rthhcSFybmD52rmn6FhO_wL4x0dmkcgFNwHBI9mqzDHi0fSfk5fbmeXafzh_vHmbTeWq5ymIqCwky57XNKmSKFrIsSqGEZcIwLhUUdY3Ac8g5ExmjRlBWU2sNLwRXypR8Qk43_658995jiLpxYVh6aVrs-qALpiBXFAYw34DWdyF4rPXKu8b4T01Br6Xpb2l6bUTDEGtpmg99J9sBfdlg9du1tTQA1xsAhzM_HHodrMPWYuU82qirzv0z4gusuXsB</recordid><startdate>200212</startdate><enddate>200212</enddate><creator>Bacon, P.A</creator><creator>Stevens, R.J</creator><creator>Carruthers, D.M</creator><creator>Young, S.P</creator><creator>Kitas, G.D</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200212</creationdate><title>Accelerated atherogenesis in autoimmune rheumatic diseases</title><author>Bacon, P.A ; Stevens, R.J ; Carruthers, D.M ; Young, S.P ; Kitas, G.D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c394t-8780853fc4de29178b7b696c26a238907ffe03505326421a612f1cca376399ab3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Arteriosclerosis - etiology</topic><topic>Arthritis, Rheumatoid - complications</topic><topic>Atherosclerosis</topic><topic>Autoimmune Diseases - complications</topic><topic>C-Reactive Protein - physiology</topic><topic>Cardiovascular disease</topic><topic>Endothelium, Vascular - physiopathology</topic><topic>Heart Diseases - etiology</topic><topic>Humans</topic><topic>Immunosuppression</topic><topic>Inflammation</topic><topic>Inflammation - etiology</topic><topic>Lupus Erythematosus, Systemic - complications</topic><topic>Models, Cardiovascular</topic><topic>Rheumatic Diseases - complications</topic><topic>Rheumatoid arthritis</topic><topic>Sphingolipids - physiology</topic><topic>Tumor Necrosis Factor-alpha - physiology</topic><topic>Vasculitis</topic><topic>Vasculitis - etiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bacon, P.A</creatorcontrib><creatorcontrib>Stevens, R.J</creatorcontrib><creatorcontrib>Carruthers, D.M</creatorcontrib><creatorcontrib>Young, S.P</creatorcontrib><creatorcontrib>Kitas, G.D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Autoimmunity reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bacon, P.A</au><au>Stevens, R.J</au><au>Carruthers, D.M</au><au>Young, S.P</au><au>Kitas, G.D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Accelerated atherogenesis in autoimmune rheumatic diseases</atitle><jtitle>Autoimmunity reviews</jtitle><addtitle>Autoimmun Rev</addtitle><date>2002-12</date><risdate>2002</risdate><volume>1</volume><issue>6</issue><spage>338</spage><epage>347</epage><pages>338-347</pages><issn>1568-9972</issn><eissn>1568-9972</eissn><abstract>The observation that systemic inflammatory rheumatic diseases such as rheumatoid arthritis (RA) are associated with a significantly increased rate of cardiovascular disease, which often occurs at a younger age than in the normal population, is particularly important given the increasing interest in the role of inflammation in atherogenesis in the general population. This review examines the accumulating evidence for accelerated atherogenesis of RA and updates the hypothesis that vasculitis plays a major role in this. Endothelial dysfunction (ECD), widely regarded as initial lesion in atherogenesis, has been shown to occur commonly in primary vasculitis. This ECD is a diffuse event, demonstrable in more than one vascular bed. It is not simply due to scarring in the vessel wall, related to the focal inflammation of the underlying vasculitis, since it may be reversed by suppression of the immune inflammation. However, the mechanisms for this ECD differ from that of the primary vasculitis. Preliminary evidence suggests that inflammatory mediators such as CRP, TNF, or sphingolipids may be involved. The diffuse ECD of vasculitis may have important consequences for both the progression of the primary disease and for cardiovascular events. A model for the role of vasculitis-induced ECD in the accelerated atherogenesis of rheumatic diseases is presented. These concepts are discussed together with the messages they suggest for ‘idiopathic’ atherosclerosis in the general population.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>12848989</pmid><doi>10.1016/S1568-9972(02)00100-3</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1568-9972
ispartof Autoimmunity reviews, 2002-12, Vol.1 (6), p.338-347
issn 1568-9972
1568-9972
language eng
recordid cdi_proquest_miscellaneous_72905910
source Elsevier:Jisc Collections:Elsevier Read and Publish Agreement 2022-2024:Freedom Collection (Reading list)
subjects Arteriosclerosis - etiology
Arthritis, Rheumatoid - complications
Atherosclerosis
Autoimmune Diseases - complications
C-Reactive Protein - physiology
Cardiovascular disease
Endothelium, Vascular - physiopathology
Heart Diseases - etiology
Humans
Immunosuppression
Inflammation
Inflammation - etiology
Lupus Erythematosus, Systemic - complications
Models, Cardiovascular
Rheumatic Diseases - complications
Rheumatoid arthritis
Sphingolipids - physiology
Tumor Necrosis Factor-alpha - physiology
Vasculitis
Vasculitis - etiology
title Accelerated atherogenesis in autoimmune rheumatic diseases
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T00%3A14%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Accelerated%20atherogenesis%20in%20autoimmune%20rheumatic%20diseases&rft.jtitle=Autoimmunity%20reviews&rft.au=Bacon,%20P.A&rft.date=2002-12&rft.volume=1&rft.issue=6&rft.spage=338&rft.epage=347&rft.pages=338-347&rft.issn=1568-9972&rft.eissn=1568-9972&rft_id=info:doi/10.1016/S1568-9972(02)00100-3&rft_dat=%3Cproquest_cross%3E72905910%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c394t-8780853fc4de29178b7b696c26a238907ffe03505326421a612f1cca376399ab3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=72905910&rft_id=info:pmid/12848989&rfr_iscdi=true